Milligan Sandra insider trades
Milligan Sandra has filed 24 Form 4s with the SEC that we hold, for Organon & Co. (OGN) (Head of Research & Development), Gossamer Bio, Inc. (GOSS) (Director), Aspira Women's Health Inc. (AWH) (Interim CEO) and Spyre Therapeutics, Inc. (SYRE) (Director). Across all of them we count 2 purchases worth $75.3K and 0 sales worth $0 reported on Form 4. None of these purchases or sales is dated in the last 12 months. The largest single trade was a purchase of 26,050 shares of Gossamer Bio, Inc. worth $50.0K, dated 2025-08-19. The first filing on our record is dated 2021-08-19 and the latest 2026-09-25.
Organon & Co. (OGN)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Gossamer Bio, Inc. (GOSS)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2023-11-15 | P, purchase reported on Form 4 | 32,000 | $25.3K | 2023-11-17 |
| 2025-08-19 | P, purchase reported on Form 4 | 26,050 | $50.0K | 2025-08-20 |
Aspira Women's Health Inc. (AWH)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Spyre Therapeutics, Inc. (SYRE)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1859810) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms